Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study

Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 un...

Full description

Saved in:
Bibliographic Details
Published inBMC Cancer Vol. 22; no. 1; pp. 486 - 10
Main Authors Abe, Shinya, Kawai, Kazushige, Nozawa, Hiroaki, Sasaki, Kazuhito, Murono, Koji, Emoto, Shigenobu, Ozawa, Tsuyoshi, Yokoyama, Yuichiro, Nagai, Yuzo, Anzai, Hiroyuki, Sonoda, Hirofumi, Yamauchi, Shinichi, Sugihara, Kenichi, Ishihara, Soichiro
Format Journal Article
LanguageEnglish
Published London Springer Science and Business Media LLC 02.05.2022
BioMed Central
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1471-2407
1471-2407
DOI10.1186/s12885-022-09615-z

Cover

Abstract Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P  < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P  = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
AbstractList Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
Abstract Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P  < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P  = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Keywords: Primary tumor location, Prognostic marker, Colorectal cancer, Chemoradiotherapy, Outcome
Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear.BACKGROUNDSeveral studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear.Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined.METHODSSubjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined.Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only.RESULTSPatients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only.Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.CONCLUSIONSPrimary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.
ArticleNumber 486
Audience Academic
Author Shinya Abe
Hiroyuki Anzai
Soichiro Ishihara
Hirofumi Sonoda
Kazushige Kawai
Yuzo Nagai
Kenichi Sugihara
Shinichi Yamauchi
Hiroaki Nozawa
Shigenobu Emoto
Yuichiro Yokoyama
Kazuhito Sasaki
Tsuyoshi Ozawa
Koji Murono
Author_xml – sequence: 1
  givenname: Shinya
  surname: Abe
  fullname: Abe, Shinya
  email: sa61451689@gmail.com
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 2
  givenname: Kazushige
  surname: Kawai
  fullname: Kawai, Kazushige
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 3
  givenname: Hiroaki
  surname: Nozawa
  fullname: Nozawa, Hiroaki
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 4
  givenname: Kazuhito
  surname: Sasaki
  fullname: Sasaki, Kazuhito
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 5
  givenname: Koji
  surname: Murono
  fullname: Murono, Koji
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 6
  givenname: Shigenobu
  surname: Emoto
  fullname: Emoto, Shigenobu
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 7
  givenname: Tsuyoshi
  surname: Ozawa
  fullname: Ozawa, Tsuyoshi
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 8
  givenname: Yuichiro
  surname: Yokoyama
  fullname: Yokoyama, Yuichiro
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 9
  givenname: Yuzo
  surname: Nagai
  fullname: Nagai, Yuzo
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 10
  givenname: Hiroyuki
  surname: Anzai
  fullname: Anzai, Hiroyuki
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 11
  givenname: Hirofumi
  surname: Sonoda
  fullname: Sonoda, Hirofumi
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
– sequence: 12
  givenname: Shinichi
  surname: Yamauchi
  fullname: Yamauchi, Shinichi
  organization: Department of Surgical Oncology, Graduate School of Medicine, The Tokyo Medical and Dental University
– sequence: 13
  givenname: Kenichi
  surname: Sugihara
  fullname: Sugihara, Kenichi
  organization: Department of Surgical Oncology, Graduate School of Medicine, The Tokyo Medical and Dental University
– sequence: 14
  givenname: Soichiro
  surname: Ishihara
  fullname: Ishihara, Soichiro
  organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo
BackLink https://cir.nii.ac.jp/crid/1870020693313518080$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/35501727$$D View this record in MEDLINE/PubMed
BookMark eNqNU9lq3DAUNSWlSdP8QB-KoKW0D061eJH7UAihiyFQ6PIsZFmeUdBIU0meLJ_XL-v1zDTJhBJqg22uzzlXOvfoabbnvNNZ9pzgY0J49S4SynmZY0pz3FSkzK8fZQekqElOC1zv3fnez45iNB3GlOOCNeWTbJ-VJSY1rQ-y36fWOKOkRWaxlCohP6BlMAsZrlAaFz6gaHrdOx0jkq5HUV8i79Dogo5aJdlZjZY-pjxoNYagndIojmFlVpOkQxuY7tFSprm3frbuFZOcadS2edu2SEE5TFoWKQn8EN8jiZxMxrsLaI4Wo01GaZd0AL0UfFwC3KygUxr7q2fZ40HaqI-278Ps56ePP06_5GdfP7enJ2e5qqs65X1REUYw4briquJVxxiuSTPUstMVBTNr0ks10KJRdcFw1ZSD7qmminNadXXJDrN2o9t7eS62JgkvjVgXfJgJGWChVgtedkTyCpe8KQpSy0aWuO4HPHQlGxrMQYtttEa3lFcX0tobQYLFNGCxGbCAAYv1gMU1sD5sWMuxW-h-siRIu7OU3T_OzMXMr0SDK0YbCgJvtgLB_xp1TGJhotLWSqf9GAWtygasYJQB9OU96LkfgwODAQUXbILRW9RMwraNGzz0VZOoOKkxZQXkrALU8T9QcPd6YRTkejBQ3yG83SEAJunLNJNjjKL9_m0X-_oOdq6lTfPo7TjFJ-4CX9x178a2v4cBAHQDUBCxGPTwfzPh90jKpHV2YY_GPkzdhiBCHzfT4dbiB1mvNixnDPSanoTXcLohsowRVhKOOWZ_AHFLSi4
CitedBy_id crossref_primary_10_1002_ijc_34959
crossref_primary_10_3390_bios13030398
crossref_primary_10_3390_jcm13133654
crossref_primary_10_1093_bjsopen_zrad085
crossref_primary_10_1159_000539981
Cites_doi 10.1200/JCO.2013.53.2473
10.1200/JCO.2009.23.3452
10.1056/NEJMoa0805019
10.1007/s00535-020-01706-7
10.1038/nm.3967
10.1016/S1470-2045(14)70330-4
10.1200/JCO.2005.205.60
10.1093/annonc/mdw235
10.1016/j.ejso.2015.01.035
10.1200/JCO.2000.18.2.412
10.1111/cas.14117
10.1186/s12957-017-1198-0
10.1097/DCR.0000000000001202
10.1038/srep29765
10.1158/1078-0432.CCR-17-2484
10.3322/caac.21660
10.1245/s10434-019-07164-7
10.1200/JCO.2009.27.4860
10.1111/j.1463-1318.2006.01017.x
10.1016/S1470-2045(16)30269-8
10.1001/jamaoncol.2017.1016
10.1136/ejhpharm-2018-001657
10.1007/s10147-019-01485-z
10.1245/s10434-019-07209-x
10.1038/s41467-019-13266-3
10.18632/oncotarget.19038
10.1111/ijcp.14863
10.1097/SLA.0000000000002206
10.4174/astr.2019.96.6.296
10.1016/j.ejca.2020.06.005
10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
10.1200/JCO.2009.27.6055
10.1016/j.ctro.2019.11.006
10.1093/annonc/mdu275
10.1001/jamaoncol.2016.4227
10.1016/j.cell.2017.07.008
10.1186/s12885-016-2412-0
10.1200/JCO.2009.21.9170
10.1093/annonc/mdx175
10.1038/nri.2016.90
10.1016/j.clcc.2020.08.007
10.1016/j.ejca.2017.07.013
10.1200/JCO.2005.03.171
10.1159/000505128
10.1097/DCR.0b013e31823c08b3
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID RYH
C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1186/s12885-022-09615-z
DatabaseName CiNii Complete
Springer Nature OA Free Journals (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



MEDLINE

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2407
EndPage 10
ExternalDocumentID oai_doaj_org_article_85b1a8605894417a9a507df0fb53f908
10.1186/s12885-022-09615-z
PMC9063292
A702345016
35501727
10_1186_s12885_022_09615_z
Genre Multicenter Study
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: Japan Society for the Promotion of Science,Japan
  grantid: C: grant number; 19K09115
– fundername: Japan Society for the Promotion of Science
  grantid: C: grant number; 18K07194
  funderid: http://dx.doi.org/10.13039/501100001691
– fundername: Japan Society for the Promotion of Science
  grantid: C: grant number; 18K07194
– fundername: ;
  grantid: C: grant number; 18K07194
– fundername: ;
  grantid: C: grant number; 19K09115
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
RYH
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
PJZUB
PPXIY
PUEGO
AAYXX
CITATION
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
2VQ
4.4
ADTOC
AHSBF
C1A
EJD
H13
IPNFZ
LGEZI
LOTEE
NADUK
NXXTH
RIG
UNPAY
ID FETCH-LOGICAL-c767t-d46131018e68c686b330719f7abe6228871dacf249c7430695fed2e2c8826b753
IEDL.DBID M48
ISSN 1471-2407
IngestDate Wed Aug 27 01:24:42 EDT 2025
Wed Aug 20 00:20:47 EDT 2025
Tue Sep 30 15:31:03 EDT 2025
Fri Sep 05 04:12:27 EDT 2025
Fri Jul 25 21:39:04 EDT 2025
Tue Jun 17 21:21:43 EDT 2025
Tue Jun 10 20:28:38 EDT 2025
Fri Jun 27 04:16:02 EDT 2025
Thu May 22 20:53:43 EDT 2025
Thu Jan 02 22:54:18 EST 2025
Thu Apr 24 22:57:45 EDT 2025
Wed Oct 01 05:06:52 EDT 2025
Sat Sep 06 07:18:36 EDT 2025
Thu Jun 26 23:11:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Primary tumor location
Chemoradiotherapy
Outcome
Prognostic marker
Colorectal cancer
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c767t-d46131018e68c686b330719f7abe6228871dacf249c7430695fed2e2c8826b753
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://link.springer.com/10.1186/s12885-022-09615-z
PMID 35501727
PQID 2666608332
PQPubID 44074
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_85b1a8605894417a9a507df0fb53f908
unpaywall_primary_10_1186_s12885_022_09615_z
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9063292
proquest_miscellaneous_2659228323
proquest_journals_2666608332
gale_infotracmisc_A702345016
gale_infotracacademiconefile_A702345016
gale_incontextgauss_ISR_A702345016
gale_healthsolutions_A702345016
pubmed_primary_35501727
crossref_primary_10_1186_s12885_022_09615_z
crossref_citationtrail_10_1186_s12885_022_09615_z
springer_journals_10_1186_s12885_022_09615_z
nii_cinii_1870020693313518080
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-02
PublicationDateYYYYMMDD 2022-05-02
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-02
  day: 02
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC Cancer
PublicationTitleAbbrev BMC Cancer
PublicationTitleAlternate BMC Cancer
PublicationYear 2022
Publisher Springer Science and Business Media LLC
BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: Springer Science and Business Media LLC
– name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References GW Ha (9615_CR6) 2019; 26
D Arnold (9615_CR21) 2017; 28
JM Lee (9615_CR29) 2019; 96
V Heinemann (9615_CR17) 2014; 15
WA Messersmith (9615_CR12) 2019; 17
Y Yamada (9615_CR45) 2019; 110
AM Kaiser (9615_CR25) 2006; 8
S Malakorn (9615_CR10) 2021; 20
S Stintzing (9615_CR18) 2016; 17
S Meltzer (9615_CR32) 2020; 21
S Haupt (9615_CR24) 2019; 10
AD Roth (9615_CR38) 2010; 28
T Yu (9615_CR34) 2017; 170
RX Zhang (9615_CR3) 2017; 15
F Petrelli (9615_CR5) 2017; 3
C Radkiewicz (9615_CR42) 2017; 84
Japanese Society for Cancer of the Colon and Rectum (9615_CR49) 2005
JM Loree (9615_CR39) 2018; 24
SL Klein (9615_CR41) 2016; 16
9615_CR44
S Karim (9615_CR7) 2017; 3
J Liu (9615_CR23) 2020; 27
J Benhattar (9615_CR40) 1996; 69
D Shida (9615_CR28) 2020; 55
S Singh (9615_CR47) 2005; 23
R Warschkow (9615_CR8) 2016; 16
K Matsuda (9615_CR2) 2020; 98
H Sung (9615_CR1) 2021; 71
H Li (9615_CR27) 2017; 8
E Van Cutsem (9615_CR14) 2009; 360
JA Sloan (9615_CR43) 2000; 18
S Ishihara (9615_CR9) 2018; 267
E Missiaglia (9615_CR35) 2014; 25
Y Hashiguchi (9615_CR13) 2020; 25
CJ Allegra (9615_CR37) 2009; 27
A Athauda (9615_CR46) 2020; 137
E Van Cutsem (9615_CR11) 2016; 27
Z Gao (9615_CR33) 2015; 6
MF Kalady (9615_CR22) 2012; 55
J Guinney (9615_CR36) 2015; 21
M Riihimäki (9615_CR31) 2016; 6
K Westberg (9615_CR26) 2015; 41
JY Douillard (9615_CR15) 2010; 28
B Klimm (9615_CR48) 2005; 23
LS Schwartzberg (9615_CR16) 2014; 32
D Shida (9615_CR4) 2019; 26
CALGB/SWOG (9615_CR19) 2006; 4
M Peeters (9615_CR20) 2010; 28
CL Sparreboom (9615_CR30) 2018; 61
References_xml – volume: 32
  start-page: 2240
  issue: 21
  year: 2014
  ident: 9615_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.53.2473
– volume: 28
  start-page: 466
  issue: 3
  year: 2010
  ident: 9615_CR38
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.3452
– volume: 360
  start-page: 1408
  issue: 14
  year: 2009
  ident: 9615_CR14
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0805019
– volume: 55
  start-page: 958
  issue: 10
  year: 2020
  ident: 9615_CR28
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-020-01706-7
– volume: 21
  start-page: 1350
  issue: 11
  year: 2015
  ident: 9615_CR36
  publication-title: Nat Med
  doi: 10.1038/nm.3967
– volume: 15
  start-page: 1065
  issue: 10
  year: 2014
  ident: 9615_CR17
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70330-4
– volume: 23
  start-page: 8003
  issue: 31
  year: 2005
  ident: 9615_CR48
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.205.60
– volume: 27
  start-page: 1386
  issue: 8
  year: 2016
  ident: 9615_CR11
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw235
– volume: 41
  start-page: 659
  issue: 5
  year: 2015
  ident: 9615_CR26
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2015.01.035
– volume: 18
  start-page: 412
  issue: 2
  year: 2000
  ident: 9615_CR43
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.2.412
– volume: 110
  start-page: 2875
  issue: 9
  year: 2019
  ident: 9615_CR45
  publication-title: Cancer Sci
  doi: 10.1111/cas.14117
– volume: 4
  start-page: 452
  issue: 6
  year: 2006
  ident: 9615_CR19
  publication-title: Clin Adv Hematol Oncol
– volume: 15
  start-page: 138
  issue: 1
  year: 2017
  ident: 9615_CR3
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-017-1198-0
– volume: 61
  start-page: 1258
  issue: 11
  year: 2018
  ident: 9615_CR30
  publication-title: Dis Colon Rectum
  doi: 10.1097/DCR.0000000000001202
– volume: 17
  start-page: 599
  issue: 5.5
  year: 2019
  ident: 9615_CR12
  publication-title: J Natl Compr Cancer Netw
– volume: 6
  start-page: 29765
  year: 2016
  ident: 9615_CR31
  publication-title: Sci Rep
  doi: 10.1038/srep29765
– volume: 24
  start-page: 1062
  issue: 5
  year: 2018
  ident: 9615_CR39
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2484
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 9615_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 26
  start-page: 1366
  issue: 5
  year: 2019
  ident: 9615_CR6
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-019-07164-7
– volume: 28
  start-page: 4697
  issue: 31
  year: 2010
  ident: 9615_CR15
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.4860
– volume: 8
  start-page: 696
  issue: 8
  year: 2006
  ident: 9615_CR25
  publication-title: Color Dis
  doi: 10.1111/j.1463-1318.2006.01017.x
– volume: 17
  start-page: 1426
  issue: 10
  year: 2016
  ident: 9615_CR18
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30269-8
– volume: 3
  start-page: 1386
  issue: 10
  year: 2017
  ident: 9615_CR7
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.1016
– volume: 27
  start-page: 267
  issue: 5
  year: 2020
  ident: 9615_CR23
  publication-title: Eur J Hosp Pharm
  doi: 10.1136/ejhpharm-2018-001657
– volume: 25
  start-page: 1
  issue: 1
  year: 2020
  ident: 9615_CR13
  publication-title: Int J Clin Oncol
  doi: 10.1007/s10147-019-01485-z
– volume: 6
  start-page: 20
  year: 2015
  ident: 9615_CR33
  publication-title: Front Microbiol
– volume: 26
  start-page: 1358
  issue: 5
  year: 2019
  ident: 9615_CR4
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-019-07209-x
– volume: 10
  start-page: 5385
  issue: 1
  year: 2019
  ident: 9615_CR24
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-13266-3
– volume: 8
  start-page: 89203
  issue: 51
  year: 2017
  ident: 9615_CR27
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19038
– ident: 9615_CR44
  doi: 10.1111/ijcp.14863
– volume: 267
  start-page: 917
  issue: 5
  year: 2018
  ident: 9615_CR9
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000002206
– volume: 96
  start-page: 296
  issue: 6
  year: 2019
  ident: 9615_CR29
  publication-title: Ann Surg Treat Res
  doi: 10.4174/astr.2019.96.6.296
– volume: 137
  start-page: 45
  year: 2020
  ident: 9615_CR46
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2020.06.005
– volume: 69
  start-page: 190
  issue: 3
  year: 1996
  ident: 9615_CR40
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
– volume: 28
  start-page: 4706
  issue: 31
  year: 2010
  ident: 9615_CR20
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.6055
– volume: 21
  start-page: 5
  year: 2020
  ident: 9615_CR32
  publication-title: Clin Transl Radiat Oncol
  doi: 10.1016/j.ctro.2019.11.006
– volume-title: JSCCR guidelines 2005 for the treatment of colorectal Cancer
  year: 2005
  ident: 9615_CR49
– volume: 25
  start-page: 1995
  issue: 10
  year: 2014
  ident: 9615_CR35
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu275
– volume: 3
  start-page: 211
  issue: 2
  year: 2017
  ident: 9615_CR5
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.4227
– volume: 170
  start-page: 548
  issue: 3
  year: 2017
  ident: 9615_CR34
  publication-title: Cell
  doi: 10.1016/j.cell.2017.07.008
– volume: 16
  start-page: 554
  year: 2016
  ident: 9615_CR8
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2412-0
– volume: 27
  start-page: 2091
  issue: 12
  year: 2009
  ident: 9615_CR37
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.21.9170
– volume: 28
  start-page: 1713
  issue: 8
  year: 2017
  ident: 9615_CR21
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx175
– volume: 16
  start-page: 626
  issue: 10
  year: 2016
  ident: 9615_CR41
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2016.90
– volume: 20
  start-page: e53
  issue: 1
  year: 2021
  ident: 9615_CR10
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/j.clcc.2020.08.007
– volume: 84
  start-page: 130
  year: 2017
  ident: 9615_CR42
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.07.013
– volume: 23
  start-page: 850
  issue: 4
  year: 2005
  ident: 9615_CR47
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.171
– volume: 98
  start-page: 230
  issue: 4
  year: 2020
  ident: 9615_CR2
  publication-title: Oncology
  doi: 10.1159/000505128
– volume: 55
  start-page: 128
  issue: 2
  year: 2012
  ident: 9615_CR22
  publication-title: Dis Colon Rectum
  doi: 10.1097/DCR.0b013e31823c08b3
SSID ssib002804395
ssj0017808
Score 2.3887541
Snippet Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal...
Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC)....
Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal...
Abstract Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
springer
nii
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 486
SubjectTerms Adenocarcinoma
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Cecum
Chemoradiotherapy
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Drug therapy
Evaluation
Female
Females
Health Promotion and Disease Prevention
Humans
Liver
Lymph nodes
Lymphatic Metastasis
Lymphatic system
Male
Males
Medical prognosis
Medicine/Public Health
Metastases
Metastasis
Mutation
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Oncology
Outcome
Patients
Peritoneum
Physiological aspects
Primary tumor location
Prognosis
Prognostic marker
Radiation therapy
RC254-282
Retrospective Studies
Review boards
Sex
Sex factors in disease
Surgery
Surgical Oncology
Surveillance
Survival
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtUwELWgCx4LxJtACwYhsaBR83QcdgVRNUhlAVTqznJsp1zpklR5UOjn8WXM2EloBCos2NxFMkmu7fHx8WPOEPJcG5gzlIHxTaWNDyOE8fMoKHERJ5BGhzrgGOB88J7tHybvjtKjc6m-8EyYkwd2FbfD0zKUHDfvcsyWJXMJDEZXQVWmcZW7MF8YxqbJ1Lh_kPGATyEynO10gMIcI5EjH1OcpP7ZYhiyav0zJl-uV6s_8c3fj03Oe6fXydWhPpHfT-V6fW542rtJboy8ku668twil0x9m1w5GHfO75AfowDomrq4SNpU9MQpTdB--NK0FPN2agQ-KmtNO_ONNjUdrBqQ6jHAip40Xe-3uEBvQwRpNwDOfMVX1tSZGU0xxfEEqBSo57GhReEXRUFRHxvxFa4r9LW2e0UldauRp_Bxag83YrFNC-_r22YKA6VWBPcuOdx7--nNvj_mb_BVxrLe1wlwBVQEM4wrxlkZA6CEeZXJ0rAIWiQLtVQVTAAV8JiA5WlldGQiBayflTCPukc26qY2DwhNNFMmKXkaqTJJecVjaVCpLTOpzLK49Eg4NadQo7g55thYCzvJ4Uw4FxDgAsK6gDjzyMv5mbHCL7R-jV4yW6Ist70AzipGZxV_c1aPPEEfEy7GdQYXsZsBdUpSoN8eeWYtUJqjxrM_x3LoOlF8_LAwejEaVQ2UUskxlALqCtW8FpabC0vADrW4vQXODjWGvyFAN0weWB7HmLYRBUfh8akbiBHbOgGUjjFg7nHkkafzbXwznterTTOgTZqjsFIUe-S-6zVzzQHDxYWHzCPZoj8tqnZ5p159tsrnORDqKIfvbk8979ffuqjptufe-Q8t_fB_tPQjci2ycIOos0k2-nYwW0Bf-_KxRaqfd8STbQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZokXgcEG8CLRiExIFGzWPjOFxQQVRdpHIAKvVmObazrLQkSx4U-vP4Zcw4TkoEWnHZQzJJ1vb48-fHfEPIc21gzpAHxjeFNj6MEMbPoiDHRZxAGh3qgGOA8_EHdnQye3-anLoFt8Ydqxww0QK1rhSuke_DQMIY8IU4er3-5mPWKNxddSk0tsjlEKgKenV6Ok64wpQHfAiU4Wy_ASzmGI8c-ZjoJPHPJ4OR1ewfkXmrXC7_xTr_Pjw57qBeJ1e7ci1_nsnV6o9B6vAmueHYJT3o3eEWuWTK2-TKsds_v0N-ORnQFe2jI2lV0HWvN0Hb7mtVU8zeqRH-qCw1bcwPWpW0s5pAqsUwK7qumtavcZneBgrSpgO0-Y6vLGlvZjTFRMcDrFIgoAtD53N_Pp9TVMlGlIXrCj2ubl5RSfs1yTP4OLVHHLHYpob3tXU1BINSK4V7l5wcvvv89sh3WRx8lbK09fUMGAPqghnGFeMsjwFWwqxIZW5YBC2ShlqqAqaBCthMwLKkMDoykQLuz3KYTd0j22VVmgeEzjRTZpbzJFL5LOEFj6VBvbbUJDJN49wj4dCcQjmJc8y0sRJ2qsOZ6F1AgAsI6wLi3CMvx2dchW-0foNeMlqiOLe9UNUL4fq64EkeSo77zRkmeJOZBNKti6DIk7jIAu6RJ-hjoo90HSFGHKRAoGYJkHCPPLMWKNBR4gmgheyaRsw_fZwYvXBGRQWlVNIFVEBdoabXxHJnYgkIoia3d8HZocbwNwQAhykEy-IYkzei7Cg8PnQD4RCuERf90SNPx9v4Zjy1V5qqQ5skQ3mlKPbI_b7XjDUHPBeXH1KPpJP-NKna6Z1y-cXqn2dAq6MMvrs39LyLv7Wp6fbG3vkfLf1wc6EfkWuRBRLEkx2y3dad2QV62uaPLQb9Bq9Xi-A
  priority: 102
  providerName: ProQuest
– databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLZokVgOiJ1ACwYhcaARWR2H24CoGqRyAEbqzXJsZxhpSEZZKPTn8ct4z1kgoqrgMofk2ZnYz18-L-97hDzXBuYMuWdcU2jjwhfCuGng5biI40mjfe1xDHA-_sCOltH7k_hkCAprxtPu45akRWo7rDl71QCScowmDlxMUxK7ZzvkcowOBF68DBbT3kHCPT6Gx5xbbvYJskr9Ex7vlOv1eVzz7yOT077pdXK1K7fyx6ncbP74NB3eJDcGTkkXvRPcIpdMeZtcOR52ze-Qn4P454b2MZG0Kui2V5mgbfe1qinm7NQIelSWmjbmO61K2lklINVicBXdVk3r1rg4b8MDadMBxnzDKkvamxlNMb3xCKYUaOfK0CxzsyyjqI2N2ArXFfpZ3bymkvYrkafwcGoPNuJrmxrqa-tqDAGlVgD3Llkevvv89sgdcje4KmFJ6-oIeAKqgRnGFeMsDwFM_LRIZG5YAD2S-FqqAiZ_CjiMx9K4MDowgQLGz3KYQ90ju2VVmgeERpopE-U8DlQexbzgoTSo0paYWCZJmDvEH7tTqEHYHPNrbISd4HAmehcQ4ALCuoA4c8jLqczQ4Bdav0EvmSxRktteqOqVGEa44HHuS467zCmmdZOpBKqtC6_I47BIPe6QJ-hjoo9vnYBFLBKgTVEM1Nshz6wFynKUeO5nJbumEdmnjzOjF4NRUcFbKjmEUUBboZLXzHJvZgm4oWa398HZocXw1wfYhokDS8MQUzai2CgUH4eBGHCtEUDnGAPWHgYOeTrdxprxrF5pqg5t4hRFlYLQIff7UTO1HLBbXHRIHJLMxtOsaed3yvUXq3qeApkOUnjuwTjyfv-ti7ruYBqd_9DTD_-v9kfkWmCBBfFlj-y2dWf2gaS2-WOLSb8AM2eJfQ
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELZKK3E8cB-BFgxC4oGmzbFxEt4KouoitUJApfJk-UpZdZusclDoz-OXMeMcNFBVIPGyWsUTJxl7Po-P-YaQ59rAnEF6xjWZNi6MEMZNA0_iIo4njPa1l2CA8-4e29mfvDuIDpbITh8LI4-xSmXKjbPh53OL2fBHHW0udNaaesI2K0DXBCOMAxdTl0Tu6SWywnCraZms7O-93_psg4tiHzcR4j5m5twbR-OSpe8fQPpSPpud54D-eY5y2Ey9Rq40-UJ8PxHz-ZnxavsGmfVf2h5TOdpoarmhTn8jgfwfqrhJrndOLd1qe-EtsmTy2-Tybrdtf4f86NhH57QNyqRFRhctzQWtm-OipJg0VCPqUpFrWplvtMhpY6mIVI3RXXRRVLVb4u6AjU-kVQMg9xWrzGkrZjTF_Mo9mlPwew8NnU7d6XRKkZwbwR2ut59bvaKCtkuhJ_Bwak9W4sebEuqry6KPQaWWgfcu2d9---nNjtslj3BVzOLa1RNwVJCOzLBEsYTJENDMT7NYSMMC0FXsa6EymH0qcKI8lkaZ0YEJFEw5mIRJ3D2ynBe5eUDoRDNlJjKJAiUnUZIloTBIExebSMRxKB3i912Hq45ZHRN8zLmdYSWMt43DoXG4bRx-6pCXwz2dwi-Ufo09cpBETnB7oSgPeQcxPImkLxLc5k4xr5xIBfj6OvMyGYVZ6iUOeYL9mbcBtgOy8a0Y_LZJBL6_Q55ZCeQFyfHg0aFoqopPP34YCb3ohLICu6Ho4jhAV0glNpJcHUkCcKlR8RoYFmgMf30YN2DmwtIwxJyRyHYKt_cmxztgrTj4k2DfSRgGDnk6FGPNeFgwN0WDMlGKrE5B6JD7rYUOmgP3Glc9YofEI9sdqXZcks--WNr1FLz5IIXnrvdW_uu1Lmq69QEJ_qKlH_6b-CNyNbAmj5a_SpbrsjFr4CXX8nEHgD8BgUG1Tw
  priority: 102
  providerName: Unpaywall
Title Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study
URI https://cir.nii.ac.jp/crid/1870020693313518080
https://link.springer.com/article/10.1186/s12885-022-09615-z
https://www.ncbi.nlm.nih.gov/pubmed/35501727
https://www.proquest.com/docview/2666608332
https://www.proquest.com/docview/2659228323
https://pubmed.ncbi.nlm.nih.gov/PMC9063292
https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-022-09615-z
https://doaj.org/article/85b1a8605894417a9a507df0fb53f908
UnpaywallVersion publishedVersion
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: KQ8
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: ABDBF
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: DIK
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources (selected full-text only)
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: RPM
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: M48
  dateStart: 20010801
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: AAJSJ
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: C6C
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1471-2407
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017808
  issn: 1471-2407
  databaseCode: U2A
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwELZ6SBwPiJtAuxiExAMN5LQdJITaqlUXqVVVWKnwYjmJUyotSckBbX8ev4wZ5ygRVdUXS5tMnI0983l8zDeEvEo1zBliR9s6S7UNI4S2I8-JcRHHUTp1U0dggPPuHtuZBZ8Ow8MF0qc76hqwunRqh_mkZuX87enPs49g8B-MwQv2rgKMFRhn7NmYwCS0zxfJMoxMHmr5bnCxq8CFyVDnAiDjrgLvg2gurWM0UBk-_wG1F_Pj48s80v8PVg67q7fJzSY_UWe_1Xz-zwC2fZfc6TxPut6qyj2yoPP75MZut7f-gPzpKELntI2cpEVGT1ouClo3P4qSYmbPFKGRqjyllT6lRU4bwxeU1BiCRU-KqrZLXMI3QYS0agCJfmGVOW3FdEoxCXIPuRSc0yNNp1N7Op1SZNBGBIbrCWpjWb2nirbrlb_h5dQcf8TP1iXUV5dFHyhKDU3uQzLb3vqyuWN3GR7shDNe22kA3gRyhmkmEiZY7APkuFHGVayZBz3C3VQlGUwRE_B0HBaFmU497SUwL2AxzLQekaW8yPUTQoOUJTqIReglcRCKTPhKI5cb16Hi3I8t4vbdKZOO_hyzcMylmQYJJlsVkKAC0qiAPLfIm-GZrsGvlN5ALRkkkbjbXCjKI9nhgBRh7CqBe9ERJn9TkQKHPM2cLA79LHKERZ6jjsk2CnaAH7nOwbkKQnDQLfLSSCB5R46ng45UU1Vy-vlgJPS6E8oK-MpEdcEW0FbI9zWSXBlJAroko9uroOzQYli6AO4wvWCR72NiR6Qkhcd7M5C98Upw-hgD3973LPJiuI0144m-XBcNyoQRUi95vkUet1YztBz4wLg0wS3CR_Y0atrxnfz4u-FGj8Dl9iJ471pveRd_66quWxus8xo9_fTarfuM3PIMpiC0rJClumz0KnixdTwhi_yQT8jyxtbe_gH82mSbE7MiNDGgBeXBxjcoZx5cWZ7t7a9__QvC2J1A
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSgcEG8CLTUIxIFGzdN2kBAqj6qhjwO00t6MkzhlpSVZ8qC0P4ofwS9jJq8SgVZcetlDPEk29vibGdvzDSFPEw0xQ2RpU6eJNsFCaDNwrAgXcSylEzuxBCY47x-wnSPvw8SfLJGffS4MHqvsMbEB6iSPcY18EwwJY-AvuM7r-TcTq0bh7mpfQqNVi119egIhW_kqfAfj-8xxtt8fvt0xu6oCZswZr8zEAwuGPFWaiZgJFkFEz-0g5SrSzHFg0tmJilMIS2KwrhYL_FQnjnZi8EVZxLFKBED-ZWjykKufT4YAz-bCEn1ijmCbJWC_wPxnx8TCKr55NjJ-TY2AwRJcyqbTf3m5fx_WHHZsr5GVOpur0xM1m_1hFLdvkOudN0u3WvW7SZZ0dotc2e_262-TXx3t6Iy22Zg0T-m85begVf01LyhWC00QbqnKElrqHzTPaN1wEMUVpnXReV5WZoHbAk1iIi1rQLfv-MiMtmI6oVhYuYdxCg7vsaZhaIZhSJGVG1Edrseo4UX5kiraroGewMtpc6QSP1sX8LyqyPvkU9pQ794hRxcyvnfJcpZn-j6hXsJi7UXCd-LI80UqXKWRH45rX3HuRgax--GUcUepjpU9ZrIJrQSTrQpIUAHZqIA8M8iL4Z6uwxdKv0EtGSSRDLy5kBfHssMWKfzIVgL3twMsKKcCBU5-klpp5LtpYAmDrKOOyTazdoA0ucXBYfN8cPoN8qSRQEKQDE8cHau6LGX46eNI6HknlObwlbHqEjigr5BDbCS5OpIExIpHzWug7NBj-GuDwYCQhQWui8UikeYUbu-ngewQtZTn898gj4dmfDKeEsx0XqOMHyCdk-Ma5F47a4aeA78alzu4QfhoPo26dtySTb80fOsBuPFOAO_d6Gfe-d9aNHQbw-z8j5F-sPij18nKzuH-ntwLD3YfkqtOAyqILatkuSpqvQaucRU9avCIks8XDYC_Ae3vxto
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLZoKxU4IHYCLTUIiQONmsniONyGpWoGWiFKpd4sx3aGkYZklIVCfx6_jPey0YiqgssckmdnYj9_-by87xHyQhuYMySOsU2qjQ1fCGNHrpPgIo4jjZ5oh2OA8-EROzjxZ6fB6YUo_ua0e78l2cY0oEpTVu2tdNoOcc72SkBVjpHFro0pSwL7fI1s8CBiMP3amE5nx7NhJyHkDu-DZS4tOfogNbr9AzqvZYvFZczz7wOUwy7qTXK9zlby55lcLi98qPZvk1sdw6TT1iXukGsmu0s2D7s99HvkVycFuqRthCTNU7pqNSdoVX_LC4oZPDVCIJWZpqX5QfOM1o0ukKow1Iqu8rKyC1yqb4IFaVkD4nzHKjPamhlNMdlxD60USOjc0Di24zimqJSNSAvXFXpdUb6mkrbrkmfwcNocc8TXNgXUVxV5HxBKGznc--Rk__2Xtwd2l8nBViELK1v7wBpQG8wwrhhniQfQMonSUCaGudAj4URLlcJUUAGjcVgUpEa7xlXA_1kCM6oHZD3LM_OIUF8zZfyEB65K_ICn3JMGNdtCE8gw9BKLTPruFKqTOcdsG0vRTHc4E60LCHAB0biAOLfIq6FM1-BXWr9BLxksUaC7uZAXc9GNd8GDZCI57jlHmORNRhKIt06dNAm8NHK4RXbQx0Qb7TrAjJiGQKL8AIi4RZ43FijSkeEpoLmsy1LEx59HRi87ozSHt1SyC6qAtkJdr5Hl1sgSUESNbm-Ds0OL4e8EQBymESzyPEzgiNKjULwfBqJDuVIAuWMMOLznWuTZcBtrxpN7mclrtAkilFhyPYs8bEfN0HLAdXEJIrRIOBpPo6Yd38kWXxsN9AiotRvBc3f7kffnb13VdbvD6PyHnn78f7XvkM1P7_bFx_jowxNyw20wBqFmi6xXRW22gb1WydMOoH4DDgmR-w
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELZKK3E8cB-BFgxC4oGmzbFxEt4KouoitUJApfJk-UpZdZusclDoz-OXMeMcNFBVIPGyWsUTJxl7Po-P-YaQ59rAnEF6xjWZNi6MEMZNA0_iIo4njPa1l2CA8-4e29mfvDuIDpbITh8LI4-xSmXKjbPh53OL2fBHHW0udNaaesI2K0DXBCOMAxdTl0Tu6SWywnCraZms7O-93_psg4tiHzcR4j5m5twbR-OSpe8fQPpSPpud54D-eY5y2Ey9Rq40-UJ8PxHz-ZnxavsGmfVf2h5TOdpoarmhTn8jgfwfqrhJrndOLd1qe-EtsmTy2-Tybrdtf4f86NhH57QNyqRFRhctzQWtm-OipJg0VCPqUpFrWplvtMhpY6mIVI3RXXRRVLVb4u6AjU-kVQMg9xWrzGkrZjTF_Mo9mlPwew8NnU7d6XRKkZwbwR2ut59bvaKCtkuhJ_Bwak9W4sebEuqry6KPQaWWgfcu2d9---nNjtslj3BVzOLa1RNwVJCOzLBEsYTJENDMT7NYSMMC0FXsa6EymH0qcKI8lkaZ0YEJFEw5mIRJ3D2ynBe5eUDoRDNlJjKJAiUnUZIloTBIExebSMRxKB3i912Hq45ZHRN8zLmdYSWMt43DoXG4bRx-6pCXwz2dwi-Ufo09cpBETnB7oSgPeQcxPImkLxLc5k4xr5xIBfj6OvMyGYVZ6iUOeYL9mbcBtgOy8a0Y_LZJBL6_Q55ZCeQFyfHg0aFoqopPP34YCb3ohLICu6Ho4jhAV0glNpJcHUkCcKlR8RoYFmgMf30YN2DmwtIwxJyRyHYKt_cmxztgrTj4k2DfSRgGDnk6FGPNeFgwN0WDMlGKrE5B6JD7rYUOmgP3Glc9YofEI9sdqXZcks--WNr1FLz5IIXnrvdW_uu1Lmq69QEJ_qKlH_6b-CNyNbAmj5a_SpbrsjFr4CXX8nEHgD8BgUG1Tw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+impact+of+primary+tumor+sidedness+and+sex+on+unresectable+post-recurrence+survival+in+resected+pathological+stage+II-III+colorectal+cancers%3A+a+nationwide+multicenter+retrospective+study&rft.jtitle=BMC+cancer&rft.au=Abe%2C+Shinya&rft.au=Kawai%2C+Kazushige&rft.au=Nozawa%2C+Hiroaki&rft.au=Sasaki%2C+Kazuhito&rft.date=2022-05-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-022-09615-z&rft.externalDocID=A702345016
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon